



**NEW AUSTRALIAN PATENT GRANTED COVERING INV043 TO EXTEND IP PROTECTION FOR PHOTOSOFT™**

**MELBOURNE (AUSTRALIA) 05 July 2023:** Invion Limited (ASX: IVX) ("Invion" or the "Company") is pleased to announce the granting of an Australian patent for Photosoft™ (Australian Patent No. 2021388872), which includes the lead compound INV043.

This patent builds upon previously granted patents to the technology in Australia and other territories that Invion has exclusive rights to.

The new patent extends the intellectual property (IP) protection for Photosoft™ for around another two decades until at least late 2041, with the original patents set to expire in 2033, and strengthens IP protection as Invion prepares to commence clinical trials using INV043 before the end of this calendar year.

**Invion's Executive Chairman and Chief Executive Officer, Thian Chew, commented:**

*"The success in securing the patent in Australia is yet another key milestone for Invion ahead of our human trials later this year. It not only gives us an important edge in developing Photosoft™ as a standalone therapy, but also in negotiating partnerships with global pharmaceutical groups to use the technology in combination therapies.*

*"Importantly, the new Australian patent will support the international patent application that is currently being progressed through the other major markets globally, including the European Patent Office."*

This announcement was approved for release by the Board of Directors.

---

**Investor and Media enquiries:**

Thian Chew (Chairman & CEO)  
T: +61 3 9692 7222  
E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

Brendon Lau (Investor & Media Relations)  
M: +61 409 341 613  
E: [brendon.lau@inviongroup.com](mailto:brendon.lau@inviongroup.com)

**About Invion**

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea to the Photosoft™ technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX).

## **ASX ANNOUNCEMENT**

### **About Photodynamic Therapy (PDT)**

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.